Nevertheless, many cancer cells, including some CRC cells, still show resistance to native TRAIL and tumor-homing TRAIL variants (Deng & Shah, 2020), suggesting the need for the combination of TRAIL with other drugs or therapies. This evidence concerns the gene TNFSF10 and colorectal carcinoma.